The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer

References

• Fojo A, Hamilton TC, Young RC, et al. Multidrug resistance in ovarian cancer. Cancer. 1987;60(8):2075–2080.
   PubMed Web of Science ®Google Scholar
• Algorashi I, Goldvaser H, Ribnikar D, et al. Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treat Rev. 2018;70:138–143.
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang ZP, Nie YZ, et al. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166.
   PubMed Web of Science ®Google Scholar
• Robey RW, Pluchino KM, Hall MD. et al. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–464.
   PubMed Web of Science ®Google Scholar
• Rigalli JP, Tocchetti GN, Weiss J. Modulation of ABC transporters by nuclear receptors: physiological pathological and pharmacological aspects. Curr Med Chem. 2019;26(7):1079–1112.
   PubMed Web of Science ®Google Scholar
• Czuba LC, Hillgren KM, Swaan PW. Post-translational modifications of transporters. Pharmacol Ther. 2018;192:88–99.
   PubMed Web of Science ®Google Scholar
• Zhang ZM, Wu JF, Luo QC, et al. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/beta-catenin pathway. Oncogene. 2016;35(36):4787–4797.
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11(7):1156–1166.
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9(1):105–127.
   PubMed Web of Science ®Google Scholar
• Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013;123(10):4131–4133.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3–29.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang LL, Di YM, et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008;15(20):1981–2039.
   PubMed Web of Science ®Google Scholar
• Mo W, Zhang JT. Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol. 2012;3(1):1–27.
   PubMedGoogle Scholar
• Ween MP, Armstrong MA, Oehler MK, et al. The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol. 2015;96(2):220–256.
   PubMed Web of Science ®Google Scholar
• Breier A, Gibalova L, Seres M, et al. New insight into P-glycoprotein as a drug target. Anticancer Agents Med Chem. 2013;13(1):159–170.
   PubMed Web of Science ®Google Scholar
• Chen QX, Bian YC, Zeng S. Involvement of AP-1 and NF-kappa B in the up-regulation of P-gp in vinblastine resistant Caco-2 Cells. Drug Metab Pharmacokinet. 2014;29(2):223–226.
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13(3):326–346.
   PubMed Web of Science ®Google Scholar
• Orlando BJ, Liao MF. ABCG2 transports anticancer drugs via a closed-to-open switch. Nat Commun. 2020;11(1):2264.
   PubMed Web of Science ®Google Scholar
• Thomas C, Tampe R. Structural and mechanistic principles of ABC transporters. Annu Rev Biochem. 2020;89:605–636.
   PubMed Web of Science ®Google Scholar
• Yin JY, Sun W, Li FC. et al. VARIDT 1.0: variability of drug transporter database. Nucleic Acids Res. 2020;48(D1):D1171.
   PubMed Web of Science ®Google Scholar
• St Laurent G, Wahlestedt C, Kapranov P. The landscape of long noncoding RNA classification. Trends Genet. 2015;31(5):239–251.
   PubMed Web of Science ®Google Scholar
• Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355.
   PubMed Web of Science ®Google Scholar
• Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–1307.
   PubMed Web of Science ®Google Scholar
• Lasda E, Circular PR. RNAs: diversity of form and function. RNA. 2014;20(12):1829–1842.
   PubMed Web of Science ®Google Scholar
• Ebbesen KK, Hansen TB, Kjems J. Insights into circular RNA biology. RNA Biol. 2017;14(8):1035–1045.
   PubMed Web of Science ®Google Scholar
• Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Xie K, Zhou HH, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19(1):47.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen L, Qin ZY, et al. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2. Acta Pharm Sin B. 2019;9(5):1008–1020.
   PubMed Web of Science ®Google Scholar
• Gambari R, Brognara E, Spandidos DA, et al. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: new trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol. 2016;49(1):5–32.
   PubMed Web of Science ®Google Scholar
• Arrigoni E, Galimberti S, Petrini M, et al. ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. Expert Opin Drug Metab Toxicol. 2016;12(12):1419–1432.
   PubMed Web of Science ®Google Scholar
• Borel F, Han R, Visser A, et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology. 2012;55(3):821–832.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Qi XM, Chen J, et al. The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. Cancer Lett. 2017;408:102–111.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhan M, Xu SW, et al. MiR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer. Cell Death Dis. 2017;8(5):e2770.
   PubMedGoogle Scholar
• Zou ZY, Zou RY, Zong D, et al. MiR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression. J Cell Mol Med. 2017;21(9):1929–1943.
   PubMed Web of Science ®Google Scholar
• Gao M, Miao LL, Liu MX, et al. MiR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7(37):59714–59726.
   PubMedGoogle Scholar
• Zeng C, Fan D, Xu Y, et al. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. Biochem Pharmacol. 2020;174:113795.
   PubMed Web of Science ®Google Scholar
• Li YM, Liu YW, Ren J, et al. MiR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neuro-Oncol. 2018;138(3):499–508.
   PubMed Web of Science ®Google Scholar
• To KKW, Zhan ZR, Litman T, et al. Regulation of ABCG2 expression at the 3ʹuntranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the s1 colon cancer cell line. Mol Cell Biol. 2008;28(17):5147–5161.
   PubMed Web of Science ®Google Scholar
• Zhu H, Wu H, Liu X. et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008;76(5):582–588.
   PubMed Web of Science ®Google Scholar
• Kaehler M, Ruemenapp J, Gonnermann D, et al. MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. Oncotarget. 2017;8(54):92018–92031.
   PubMedGoogle Scholar
• Xie MX, Fu ZY, Cao JX, et al. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-kappa B signaling pathway in breast cancer. Biomed Pharmacother. 2018;102:286–294.
   PubMed Web of Science ®Google Scholar
• Zheng SZ, Sun P, Wang JP, et al. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells. World J Gastroenterol. 2019;25(22):2752–2762.
   PubMed Web of Science ®Google Scholar
• Xie ZY, Wang FF, Xiao ZH, et al. Overexpressing microRNA-34a overcomes ABCG2-mediated drug resistance to 5-FU in side population cells from colon cancer via suppressing DLL1. J Biochem. 2020;167(6):557–564.
   PubMed Web of Science ®Google Scholar
• Li Y, Gong P, Hou JX, et al. MiR-34a regulates multidrug resistance via positively modulating OAZ2 signaling in colon cancer cells. J Immunol Res. 2018;2018:7498514.
   PubMed Web of Science ®Google Scholar
• Shi XX, Valizadeh A, Mir SM, et al. MiRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. Eur J Pharmacol. 2020;880:173138.
   PubMed Web of Science ®Google Scholar
• Wang HM, Deng ZW, Chen XH, et al. Downregulation of miR-222-3p reverses doxorubicin-resistance in LoVo cells through upregulating forkhead box protein P2 (FOXP2) protein. Med Sci Monit. 2019;25:2169–2178.
   PubMed Web of Science ®Google Scholar
• Li CY, Zou JH, Zheng GQ, et al. MiR-30a decreases multidrug resistance (MDR) of gastric cancer cells. Med Sci Monit. 2016;22:4509–4515.
   PubMed Web of Science ®Google Scholar
• Bao J, Xu Y, Wang QY, et al. MiR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother. 2017;92:1030–1037.
   PubMed Web of Science ®Google Scholar
• Meng QC, Liang C, Hua J, et al. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics. 2020;10(9):3967–3979.
   PubMed Web of Science ®Google Scholar
• Ma J, Wang T, Guo R, et al. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J Drug Target. 2015;23(6):519–524.
   PubMed Web of Science ®Google Scholar
• Liu H, Song XL, Hou JQ, et al. Posttranscriptional regulation of human antigen R by miR-133b enhances docetaxel cytotoxicity through the inhibition of ATP-binding cassette subfamily G member 2 in prostate cancer cells. DNA Cell Biol. 2018;37(3):210–219.
   PubMed Web of Science ®Google Scholar
• To KKW, Leung WW, Ng SSM. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp Cell Res. 2015;338(2):222–231.
   PubMed Web of Science ®Google Scholar
• Li SC, Yang JJ, Wang J, et al. Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. Cell Biosci. 2018;8:9.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Zhang DL, Fu C, et al. MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1 alpha feedback loop. Eur Rev Med Pharmacol Sci. 2016;20(10):2020–2027.
   PubMed Web of Science ®Google Scholar
• Jin YH, Wang M, Hu HG, et al. Overcoming sternness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. Int J Biol Macromol. 2018;117:445–453.
   PubMed Web of Science ®Google Scholar
• Long QZ, Du YF, Liu XG, et al. MiR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma. Tumor Biol. 2015;36(9):7017–7026.
   PubMedGoogle Scholar
• Zhao L, Wang Y, Jiang LY, et al. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J Exp Clin Cancer Res. 2016;35:25.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao L, Xiao QH, et al. MiR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. Gynecol Oncol. 2016;141(3):592–601.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen X, Xiu YL, et al. MicroRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. J Ovarian Res. 2014;7:84.
   PubMed Web of Science ®Google Scholar
• Tian J, Xu YY, Li L, et al. MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2. Am J Transl Res. 2017;9(3):1127–1138.
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463.
   PubMed Web of Science ®Google Scholar
• Gao ZZ, Chen MJ, Tian XK, et al. A novel human lncRNA SANT1 cis-regulates the expression of SLC47A2 by altering SFPQ/E2F1/HDAC1 binding to the promoter region in renal cell carcinoma. RNA Biol. 2019;16(7):940–949.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fang ZH, Hong M, et al. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10(1):105–112.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang R, Yang DX, et al. Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell Physiol Biochem. 2018;51(1):113–128.
   PubMedGoogle Scholar
• Lee HJ, Gopalappa R, Sunwoo H, et al. En bloc and segmental deletions of human XIST reveal X chromosome inactivation-involving RNA elements. Nucleic Acids Res. 2019;47(8):3875–3887.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Jiao CJ, Lin YQ, et al. LncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells. DNA Cell Biol. 2017;36(1):18–25.
   PubMed Web of Science ®Google Scholar
• Chen ZL, Pan TT, Jiang DC, et al. The lncRNA-GAS5/miR-221-3p/DKK2 axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the Wnt/beta-catenin signaling pathway. Mol Ther-Nucl Acids. 2020;19:1434–1448.
   PubMedGoogle Scholar
• Chang L, Hu Z, Zhou ZY, et al. Linc00518 contributes to multidrug resistance through regulating the miR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48(1):16–28.
   PubMedGoogle Scholar
• Xu ST, Xu JH, Zheng ZR, et al. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. Biomed Pharmacother. 2017;96:14–21.
   PubMed Web of Science ®Google Scholar
• Chen JW, Shin VY, Siu MT, et al. MiR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer. 2016;16(1):887.
   PubMedGoogle Scholar
• Shin VY, Siu JM, Cheuk I, et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer. 2015;112(11):1751–1759.
   PubMed Web of Science ®Google Scholar
• Wu C, Su J, Long W, et al. LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma. J Cell Mol Med. 2020;24(20):12094–12106.
   PubMed Web of Science ®Google Scholar
• An Q, Zhou LY, Xu N. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018;103:415–420.
   PubMed Web of Science ®Google Scholar
• Kong J, Qiu Y, Li Y, et al. TGF-beta1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. Biopharm Drug Dispos. 2019;40(2):70–80.
   PubMed Web of Science ®Google Scholar
• Yin XL, Liao YJ, Xiong WW, et al. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression. Clin Exp Pharmacol Physiol. 2020;47(6):1049–1057.
   PubMed Web of Science ®Google Scholar
• Hu BL, Zhang HF, Wang ZP, et al. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biol Ther. 2017;18(12):974–983.
   PubMed Web of Science ®Google Scholar
• Zhang EB, Han L, Yin DD, et al. H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma. Nucleic Acids Res. 2017;45(6):3086–3101.
   PubMed Web of Science ®Google Scholar
• Han Z, Shi LY. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochem Biophys Res Commun. 2018;495(1):947–953.
   PubMed Web of Science ®Google Scholar
• Wang RM, Zhang TT, Yang Z, et al. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med. 2018;22(9):4068–4075.
   PubMed Web of Science ®Google Scholar
• Zhang F, Ni HW, Li XM, et al. LncRNA FENDRR attenuates adriamycin resistance via suppressing MDR1 expression through sponging HuR and miR-184 in chronic myelogenous leukaemia cells. FEBS Lett. 2019;593(15):1993–2007.
   PubMed Web of Science ®Google Scholar
• Gao RR, Fang C, Xu JC, et al. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys. 2019;663:183–191.
   PubMed Web of Science ®Google Scholar
• Hu HQ, Yang L, Li LJ, et al. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis. Biochem Biophys Res Commun. 2018;503(4):2400–2406.
   PubMed Web of Science ®Google Scholar
• Huang H, Chen J, Ding CM, et al. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol Med. 2018;22(6):3238–3245.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Luo Y, Xu WL, et al. Silencing long intergenic non-coding RNA 00707 enhances cisplatin sensitivity in cisplatin-resistant non-small-cell lung cancer cells by sponging miR-145. Oncol Lett. 2019;18(6):6261–6268.
   PubMed Web of Science ®Google Scholar
• Ma YL, Fan B, Ren ZT, et al. Long noncoding RNA DANCR contributes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway. Oncol Targets Ther. 2019;12:5485–5497.
   PubMed Web of Science ®Google Scholar
• Song L, Zhou ZG, Gan YB, et al. Long noncoding RNA OIP5-AS1 causes cisplatin resistance in osteosarcoma through inducing the LPAAT/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p. J Cell Biochem. 2019;120(6):9656–9666.
   PubMed Web of Science ®Google Scholar
• Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–641.
   PubMed Web of Science ®Google Scholar
• Zhang CL, Zhu KP, Ma XL. Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Lett. 2017;396:66–75.
   PubMed Web of Science ®Google Scholar
• Ji LY, Liu X, Zhang SW, et al. The novel triazolonaphthalimide derivative LSS-11 synergizes the anti-proliferative effect of paclitaxel via STAT3-dependent MDR1 and MRP1 downregulation in chemoresistant lung cancer cells. Molecules (Basel). 2017;22(11):1822.
   Web of Science ®Google Scholar
• Fang ZX, Chen WY, Yuan ZG, et al. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–542.
   PubMed Web of Science ®Google Scholar
• Wang LM, Zhang YW, Xin XY. Long non-coding RNA MALAT1 aggravates human retinoblastoma by sponging miR-20b-5p to upregulate STAT3. Pathol Res Pract. 2020;216(6):152977.
   PubMed Web of Science ®Google Scholar
• Jiang BH, Li YH, Qu XF, et al. Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin-resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med. 2018;42(5):2801–2810.
   PubMed Web of Science ®Google Scholar
• Shang C, Sun L, Zhang JL, et al. Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget. 2017;8(9):15393–15398.
   PubMedGoogle Scholar
• Wang Y, Zhang DX, Wu KC. et al. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. Mol Cell Biol. 2014;34(17):3182–3193.
   PubMed Web of Science ®Google Scholar
• Huang PD, Li FY, Li L, et al. LncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells. Sci Rep. 2018;8(1):17970.
   PubMedGoogle Scholar
• Zhang XO, Dong R, Zhang Y, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016;26(9):1277–1287.
   PubMed Web of Science ®Google Scholar
• Su M, Xiao YH, Ma JL, et al. Circular RNAs in cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. Mol Cancer. 2019;18(1):90.
   PubMedGoogle Scholar
• Zheng FS, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacother. 2020;124:109828.
   PubMed Web of Science ®Google Scholar
• Zhu KP, Ma XL, Zhang CL. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci. 2018;14(3):321–330.
   PubMed Web of Science ®Google Scholar
• Zhu KP, Ma XL, Zhang L. et al., Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics. 10(10): 1327–1346. 2018.
   PubMed Web of Science ®Google Scholar
• Gong PF, Xu RF, Zhuang QF, et al. A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer. Biomed Pharmacother. 2020;126:110059.
   Google Scholar
• Xu QY, Xie MJ, Huang J, et al. Effect of circ MTHFD2 on resistance to pemetrexed in gastric cancer through regulating expression of miR-124.. Eur Rev Med Pharmacol Sci. 2019;23(23):10290–10299.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu J, Huan J, et al. Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7. Cancer Cell Int. 2020;20(1):334.
   PubMed Web of Science ®Google Scholar
• Huang W, Huang F, Feng C. CircFoxo3 promotes adriamycin resistance through regulation of miR-199a-5p/ATP binding cassette subfamily C member 1 axis in hepatocellular carcinoma. Onco Targets Ther. 2020;13:5113–5122.
   PubMed Web of Science ®Google Scholar
• Dong Y, Xu T, Zhong SP, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296–5p. Life Sciences. 2019;239:116984.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Huang V, Xu X, et al. Widespread and functional RNA circularization in localized prostate cancer. Cell. 2019;176(4):831–843 e822. .
   PubMed Web of Science ®Google Scholar
• Steinbichler TB, Dudas J, Skvortsov S, et al. Therapy resistance mediated by exosomes. Mol Cancer. 2019;18(1):58. .
   PubMed Web of Science ®Google Scholar
• Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010;73(10):1907–1920.
   PubMed Web of Science ®Google Scholar
• Mashouri L, Yousefi H, Aref AR, et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75.
   PubMed Web of Science ®Google Scholar
• Kanlikilicer P, Bayraktar R, Denizli M, et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100–112.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Du LT, et al. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18(1):43.
   PubMedGoogle Scholar
• Takahashi K, Yan IK, Wood J. et al. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12(10):1377–1387.
   PubMed Web of Science ®Google Scholar
• Chen YT, Liu L, Li J, et al. Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract. 2019;215(3):470–477.
   PubMed Web of Science ®Google Scholar
• Ding CY, Yi XH, Wu XY, et al. Exosome-mediated transfer of circRNA circNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020;479:1–12.
   PubMed Web of Science ®Google Scholar
• Ratti M, Lampis A, Ghidini M, et al. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside. Target Oncol. 2020;15(3):261–278.
   PubMed Web of Science ®Google Scholar
• Boca S, Gulei D, Zimta AA, et al. Nanoscale delivery systems for microRNAs in cancer therapy. Cell Mol Life Sci. 2020;77(6):1059–1086.
   PubMed Web of Science ®Google Scholar
• Yi H, Liu L, Sheng N, et al. Synergistic therapy of doxorubicin and miR-129-5p with self-cross-linked bioreducible polypeptide nanoparticles reverses multidrug resistance in cancer cells. Biomacromolecules. 2016;17(5):1737–1747.
   PubMed Web of Science ®Google Scholar
• Wei SG, Gao JN, Zhang MP, et al. Dual delivery nanoscale device for miR-451 and adriamycin co-delivery to combat multidrug resistant in bladder cancer. Biomed Pharmacother. 2020;122:109473.
   PubMed Web of Science ®Google Scholar
• He JY, Gong CL, Qin J, et al. Cancer cell membrane decorated silica nanoparticle loaded with miR495 and doxorubicin to overcome drug resistance for effective lung cancer therapy. Nanoscale Res Lett. 2019;14(1):339.
   PubMed Web of Science ®Google Scholar
• Xue HY, Yu ZY, Liu Y, et al. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. Int J Nanomed. 2017;12:5271–5287.
   PubMed Web of Science ®Google Scholar
• Monroig PD, Chen L, Zhang SX, et al. Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Del Rev. 2015;81:104–116.
   PubMed Web of Science ®Google Scholar
• Yan LB, Ding BC, Liu HR, et al. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. Theranostics. 2019;9(26):8377–8391.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Wang N, Liu PX, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget. 2014;5(16):7013–7026.
   PubMedGoogle Scholar
• La XQ, Zhang LC, Li ZY, et al. (-)epigallocatechin gallate (EGCG) enhances the sensitivity of colorectal cancer cells to 5-FU by inhibiting GRP78/NF-kappa B/miR-155-5p/MDR1 pathway. J Agric Food Chem. 2019;67(9):2510–2518.
   PubMed Web of Science ®Google Scholar
• Nagiah S, Phulukdaree A, Chuturgoon A. Inverse association between microRNA-124a and ABCC4 in HepG2 cells treated with antiretroviral drugs. Xenobiotica. 2016;46(9):825–830.
   PubMed Web of Science ®Google Scholar
• Huang CX, Huang SL, Li HR. et al. The effects of ultrasound exposure on P-glycoprotein-mediated multidrug resistance in vitro and in vivo. J Exp Clin Cancer Res. 2018;37(1):232.
   PubMedGoogle Scholar
• Palazzo AF, Lee ES. Non-coding RNA: what is functional and what is junk? Front Genet. 2015;6:2.
   PubMed Web of Science ®Google Scholar
• Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–694.
   PubMed Web of Science ®Google Scholar
• Shalem O, Sanjana NE, Hartenian E, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–87.
   PubMed Web of Science ®Google Scholar
• Yang J, Meng XD, Pan JC, et al. CRISPR/Cas9-mediated noncoding RNA editing in human cancers. RNA Biol. 2018;15(1):35–43.
   PubMed Web of Science ®Google Scholar